<DOC>
	<DOCNO>NCT02101866</DOCNO>
	<brief_summary>This Phase 1 study aim determine oral bioavailability single dose new vapendavir tablet formulation compare previous vapendavir capsule formulation . The safety drug product also assess .</brief_summary>
	<brief_title>A Study Compare Oral Bioavailability Single Doses Two Vapendavir Drug Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Must male female 18 55 year age ( inclusive ) BMI 18 30 kg/m2 ( inclusive ) , weight â‰¥50 kg time screen Capable give write informed consent Subject able understand comply protocol requirement , instruction restriction Healthy basis physical examination , medical history , medication usage , VS , ECGs , clinical laboratory test Female subject must nonchildbearing potential Male subject must agree use double barrier method birth control Positive result Hepatitis B , Hepatitis C , HIV Frequent use tobacco product , include cigarette , cigar , chew tobacco A medical history significant hematological , gastrointestinal , respiratory , renal , hepatic , cerebrovascular , immunologic , psychiatric cardiovascular disease event ; Current recent respiratory infection Presence history significant allergy Clinically significant abnormality note ECG Screening vital sign represent sustain elevated blood pressure Presence significant gastrointestinal abnormality Safety laboratory abnormality note screen clinically significant Current define history abuse alcohol illicit drug A positive pregnancy test screen Poor vein access fear venipuncture sight blood</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Bioavailability Study</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>